• Scancell agreed to acquire Neuphoria in an all-share merger, creating a combined company operating as Scancell with a planned Nasdaq listing under “SCLT”.
• Neuphoria shareholders will receive 37.77 Scancell ADSs per share, implying about 20,414,065 ADSs, or roughly 13.7% of Scancell’s enlarged ordinary share capital.
• Neuphoria holders will also get non-transferable CVRs tied to milestones and monetization of partnered assets, certain IP, and an Australian R&D tax credit.
• Scancell targets up to $89 million of equity and debt financing, including $39.1 million private placement, about $12 million UK placing, up to $3 million retail offer, and up to $25 million debt.
• Closing is expected in late Q4 2026, subject to shareholder votes and Neuphoria maintaining at least $10 million of net cash at year-end 2026 or completion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuphoria Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-081052), on July 24, 2026, and is solely responsible for the information contained therein.